A Study to Compare the Bioavailability (BA) of Dexlansoprazole Delayed-release Capsules
Status: | Completed |
---|---|
Conditions: | Healthy Studies |
Therapuetic Areas: | Other |
Healthy: | No |
Age Range: | 18 - 55 |
Updated: | 3/23/2019 |
Start Date: | January 10, 2019 |
End Date: | March 10, 2019 |
A Phase 1, Randomized, Open-Label, Single-Dose, Two-Period Crossover Study to Compare the Bioavailability of Dexlansoprazole Capsules Manufactured by Takeda GmbH Relative to Dexlansoprazole Capsules Manufactured by Takeda Osaka Following a High-Fat Meal
The purpose of this study is to assess the BA of 30 or 60 milligram (mg) dexlansoprazole
capsule manufactured at TOB (Takeda GmbH Plant Oranienburg) to the corresponding 30 or 60 mg
dexlansoprazole manufactured at TPC (Takeda Pharmaceutical Company Ltd.).
capsule manufactured at TOB (Takeda GmbH Plant Oranienburg) to the corresponding 30 or 60 mg
dexlansoprazole manufactured at TPC (Takeda Pharmaceutical Company Ltd.).
The drug being tested in this study is called dexlansoprazole. Dexlansoprazole is being
tested in healthy participants to compare the BA of dexlansoprazole capsules manufactured by
TOB relative to dexlansoprazole capsules manufactured by TPC, under fed conditions. The study
consists of two parts: Part 1 participants will receive dexlansoprazole 30 mg capsules
manufactured by TOB and TPC in a crossover fashion; Part 2 participants will receive
dexlansoprazole 60 mg capsules manufactured by TOB and TPC in a crossover fashion.
The study will enroll approximately 120 participants. Participants will be randomly assigned
(by chance, like flipping a coin) to 1 of the 4 treatment sequences as following:
- Part 1: Dexlansoprazole 30 mg (TOB) + Dexlansoprazole 30 mg (TPC)
- Part 1: Dexlansoprazole 30 mg (TPC) + Dexlansoprazole 30 mg (TOB)
- Part 2: Dexlansoprazole 60 mg (TOB) + Dexlansoprazole 60 mg (TPC)
- Part 2: Dexlansoprazole 60 mg (TPC) + Dexlansoprazole 60 mg (TOB)
All participants will be asked to take capsule of assigned dexlansoprazole on Day 1, 30
minutes following the beginning of a high-fat/high calorie breakfast of each treatment
period.
This single center trial will be conducted in the United States. The overall time to
participate in this study is approximately 86 days. Participants will be contacted by phone
call approximately 10 days after the last dose of study drug for a follow-up assessment.
tested in healthy participants to compare the BA of dexlansoprazole capsules manufactured by
TOB relative to dexlansoprazole capsules manufactured by TPC, under fed conditions. The study
consists of two parts: Part 1 participants will receive dexlansoprazole 30 mg capsules
manufactured by TOB and TPC in a crossover fashion; Part 2 participants will receive
dexlansoprazole 60 mg capsules manufactured by TOB and TPC in a crossover fashion.
The study will enroll approximately 120 participants. Participants will be randomly assigned
(by chance, like flipping a coin) to 1 of the 4 treatment sequences as following:
- Part 1: Dexlansoprazole 30 mg (TOB) + Dexlansoprazole 30 mg (TPC)
- Part 1: Dexlansoprazole 30 mg (TPC) + Dexlansoprazole 30 mg (TOB)
- Part 2: Dexlansoprazole 60 mg (TOB) + Dexlansoprazole 60 mg (TPC)
- Part 2: Dexlansoprazole 60 mg (TPC) + Dexlansoprazole 60 mg (TOB)
All participants will be asked to take capsule of assigned dexlansoprazole on Day 1, 30
minutes following the beginning of a high-fat/high calorie breakfast of each treatment
period.
This single center trial will be conducted in the United States. The overall time to
participate in this study is approximately 86 days. Participants will be contacted by phone
call approximately 10 days after the last dose of study drug for a follow-up assessment.
Inclusion Criteria:
1. Has a body mass index (BMI) from 18 to 30 kilogram per square meter (kg/m^2), at
Screening.
2. Is willing and able to consume the high-fat/high-calorie breakfast administered during
the study.
Exclusion Criteria:
1. Has a history of drug abuse (defined as any illicit drug use) or drug addiction in the
12 months prior to Screening or a history of alcohol abuse (defined as regular
consumption exceeding 21 units per week [1 unit equal (=) 12 ounces (oz) beer, 1.5 oz
hard liquor, or 5 oz wine]) within 1 year prior to the Screening Visit, or is
unwilling to agree to abstain from alcohol and drugs throughout the study.
2. Has a positive test result for drugs of abuse (defined as any illicit drug use) or
alcohol at Screening or Check-in (Day -1 of Period 1).
3. Has received any known hepatic or renal clearance altering agents (example,
erythromycin, cimetidine, barbiturates, phenothiazines, fluvoxamine, etc) for a period
of 28 days prior to Day 1 of Period 1.
4. Has donated blood products (such as plasma) within 30 days or has donated whole blood
or lost 450 milliliter (mL) or more of his or her blood volume, or had a transfusion
of any blood product within 56 days prior to Day 1 of Period 1.
5. With the exception of acetaminophen, the subject has taken any excluded medication,
supplements, or food products or beverages containing grapefruit or grapefruit juice,
star fruit or star fruit juice, Seville-type (sour) oranges and marmalade, apple,
orange, or pineapple juice, vegetables from the mustard green family (example, kale,
broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, mustard), and
charbroiled meats. Hormonal contraception and hormone replacement therapy are allowed,
as long as the subject has been on a stable dose for a minimum of 90 days prior to Day
1 of Period 1.
6. Has used nicotine-containing products (including but not limited to cigarettes, pipes,
cigars, chewing tobacco, nicotine patch nicotine gum, e-cigarettes) within 28 days
prior to Check-in (Day -1 of Period 1), or has a positive cotinine test at Screening
or Check-in (Day -1 of Period 1), or is unwilling to abstain from these products for
the duration of the study.
7. Has received dexlansoprazole or lansoprazole in a previous clinical study or as a
therapeutic agent within 6 months of screening.
We found this trial at
1
site